Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.
23h
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s ...
Precision Biosciences' ARCUS platform offers high precision and versatility, supporting in vivo gene editing therapies, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback